HomeFileStructural heart disease

Structural heart disease

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality....

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary...